Nucleophosmin (NPM1) gene mutations, occurring in approximately 30% of adult acute myeloid leukemia (AML) cases, and in 50–60% of AML cases with a normal karyotype, represent one of the most frequent molecular lesions observed in AML [1–3]. This evidence concerns the gene NPM1 and acute myeloid leukemia.